To Detect The Expression Of HOCT1 By Semi-quantity RT-PCR In Chronic Myelogeneous Leukemia Patients Administered By Imatinib Mesylate

Objective To monitor hOCT1 gene expression and its variations around the course of response or drug resistance to imatinib administered to patients with chronic myelogenous leukemia ( CML),so as to detect hOCT1 gene expression and its clincal variations, and explore the correlation between dynamic changes of hOCT1 gene expression and disease response or resistance to imatinib.Material and Methods By RT-PCR(semi-quantity RT-PCR,SQ-PCR), hOCT1 gene mRNA levels were detected from 9 couples of (18) samples on two different time points around the course of response or drug resistance to imatinib in patients with chronic myelogenous leukemia respectively. The results of their SQ-PCRs were compared with clincal presentations,laboratory detections and cytogenetic findings thereof ,to get some information on the correlation between changes of hOCT1 gene levels and disease response or resistance to imatinib.Results The relative expression levels of hOCT1 gene were in normal distribution in both test 1 and test 2 in 5 patients with chronic myelogenous leukemia in chronic phase.,with mean±standarad deviation equal to 0.4246 + 0.2067, 0.4858 + 0.1943, respectively, with P value equal to 0.705and without stastistcal significance. The relative expression levels ofhOCT1 gene between two tests increased in 3 patients and decreased in 1patient of 4 patiets with chronic myelogenous leukemia in advanced phasesrespectively.Conclusion This study suggested that:1.Semi-quantity RT-PCR was a method available and simple ,applied to qualitative research and relative quantitative analysis,detecting hOCT1 gene expression and its variations in chronic myelogenous leukemia patients administered imatinib and possibly applied to the detection of imatinib response or resistance and the research of its mechanism in chronic myelogenous leukemia.2.In the study,no significant differences in both hOCT1 gene expression and its variations is there in chronic myelogenous leukemia patients administered imatinib in chronic phase.3. In the study,no consistency in both hOCT1 gene expression and its variations is there in chronic myelogenous leukemia patients administered imatinib in advanced phases.